![Angelo S. Botter](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Angelo S. Botter
Keine laufenden Positionen mehr
Karriereverlauf von Angelo S. Botter
Ehemalige bekannte Positionen von Angelo S. Botter
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
MEDEXUS PHARMACEUTICALS INC. | Direktor/Vorstandsmitglied | 10.12.2013 | 02.06.2014 |
Advanced Viral Research Corp.
![]() Advanced Viral Research Corp. Pharmaceuticals: MajorHealth Technology Advanced Viral Research Corp. is a biopharmaceutical company, engages in the research, development, and commercialization of small molecule therapeutics that address medical needs for various degenerative conditions. Its products include AVR118, a cytoprotective drug composed of a complex mixture of protein and ribonucleic acid components; AVR123, a form of AVR118 specially designed for dermatology applications, which is in Phase II clinical trials; AVR147, an inhibitor of a cancer target known as a proteasome; AVR168 that is a natural product, which inhibits a member of a family of motor proteins that are responsible for the assembly and function of microtubules during cell division. The company was founded in July 1985 and is headquartered in Yonkers, NY. | Direktor/Vorstandsmitglied | 31.05.2006 | 23.03.2009 |
Ausbildung von Angelo S. Botter
McGill University | Undergraduate Degree |
Statistik
International
Kanada | 3 |
Vereinigte Staaten | 2 |
Operativ
Director/Board Member | 2 |
Undergraduate Degree | 1 |
Sektoral
Health Technology | 3 |
Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
MEDEXUS PHARMACEUTICALS INC. | Health Technology |
Private Unternehmen | 1 |
---|---|
Advanced Viral Research Corp.
![]() Advanced Viral Research Corp. Pharmaceuticals: MajorHealth Technology Advanced Viral Research Corp. is a biopharmaceutical company, engages in the research, development, and commercialization of small molecule therapeutics that address medical needs for various degenerative conditions. Its products include AVR118, a cytoprotective drug composed of a complex mixture of protein and ribonucleic acid components; AVR123, a form of AVR118 specially designed for dermatology applications, which is in Phase II clinical trials; AVR147, an inhibitor of a cancer target known as a proteasome; AVR168 that is a natural product, which inhibits a member of a family of motor proteins that are responsible for the assembly and function of microtubules during cell division. The company was founded in July 1985 and is headquartered in Yonkers, NY. | Health Technology |
- Börse
- Insiders
- Angelo S. Botter
- Erfahrung